|
1
|
Ha R, Chow D and Wynn R: Global trend in
breast cancer imaging research 1992–2012: Bibliometric study. AJR
Am J Roentgenol. 202:696–697. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Youlden DR, Cramb SM, Yip CH and Baade PD:
Incidence and mortality of female breast cancer in the Asia-Pacific
region. Cancer Biol Med. 11:101–115. 2014.PubMed/NCBI
|
|
3
|
Shi XJ, Au WW, Wu KS, Chen LX and Lin K:
Mortality characteristics and prediction of female breast cancer in
China from 1991 to 2011. Asian Pac J Cancer Prev. 15:2785–2791.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang J, Liang Q, Lei Y, Yao M, Li L, Gao
X, Feng J, Zhang Y, Gao H, Liu DX, et al: SOX4 induces
epithelial-mesenchymal transition and contributes to breast cancer
progression. Cancer Res. 72:4597–4608. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ansieau S: EMT in breast cancer stem cell
generation. Cancer Lett. 338:63–68. 2013. View Article : Google Scholar
|
|
6
|
Sarkar FH, Li Y, Wang Z and Kong D:
Pancreatic cancer stem cells and EMT in drug resistance and
metastasis. Minerva Chir. 64:489–500. 2009.PubMed/NCBI
|
|
7
|
Acloque H, Adams MS, Fishwick K,
Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions:
The importance of changing cell state in development and disease. J
Clin Invest. 119:1438–1449. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Anderson MJ, Viars CS, Czekay S, Cavenee
WK and Arden KC: Cloning and characterization of three human
forkhead genes that comprise an FKHR-like gene subfamily. Genomics.
47:187–199. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gross DN, van den Heuvel AP and Birnbaum
MJ: The role of FoxO in the regulation of metabolism. Oncogene.
27:2320–2336. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Goto T, Takano M, Albergaria A, Briese J,
Pomeranz KM, Cloke B, Fusi L, Feroze-Zaidi F, Maywald N, Sajin M,
et al: Mechanism and functional consequences of loss of FOXO1
expression in endometrioid endometrial cancer cells. Oncogene.
27:9–19. 2008. View Article : Google Scholar
|
|
12
|
Maekawa T, Maniwa Y, Doi T, Nishio W,
Yoshimura M, Ohbayashi C, Hayashi Y and Okita Y: Expression and
localization of FOXO1 in non-small cell lung cancer. Oncol Rep.
22:57–64. 2009.PubMed/NCBI
|
|
13
|
Zhang H, Pan Y, Zheng L, Choe C, Lindgren
B, Jensen ED, Westendorf JJ, Cheng L and Huang H: FOXO1 inhibits
Runx2 transcriptional activity and prostate cancer cell migration
and invasion. Cancer Res. 71:3257–3267. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zheng G, Jia X, Peng C, Deng Y, Yin J,
Zhang Z, Li N, Deng M, Liu X, Liu H, et al: The
miR-491-3p/mTORC2/FOXO1 regulatory loop modulates chemo-sensitivity
in human tongue cancer. Oncotarget. 6:6931–6943. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu ZH, Shun WW, Hang JB, Gao BL and Hu JA:
Posttranslational modifications of FOXO1 regulate epidermal growth
factor receptor tyrosine kinase inhibitor resistance for non-small
cell lung cancer cells. Tumour Biol. 36:5485–5495. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang J, Yang H, Li W, Xu H, Yang X and Gan
L: Thioredoxin 1 upregulates FOXO1 transcriptional activity in drug
resistance in ovarian cancer cells. Biochim Biophys Acta.
1852:395–405. 2015. View Article : Google Scholar
|
|
17
|
Duan X, Kong Z, Liu Y, Zeng Z, Li S, Wu W,
Ji W, Yang B, Zhao Z and Zeng G: β-Arrestin2 contributes to cell
viability and proliferation via the down-regulation of FOXO1 in
castration-resistant prostate cancer. J Cell Physiol.
230:2371–2381. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chang YM, Kung HJ and Evans CP:
Nonreceptor tyrosine kinases in prostate cancer. Neoplasia.
9:90–100. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sato I, Obata Y, Kasahara K, Nakayama Y,
Fukumoto Y, Yamasaki T, Yokoyama KK, Saito T and Yamaguchi N:
Differential trafficking of Src, Lyn, Yes and Fyn is specified by
the state of palmitoylation in the SH4 domain. J Cell Sci.
122:965–975. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Szalmás A, Gyöngyösi E, Ferenczi A, László
B, Karosi T, Csomor P, Gergely L, Veress G and Kónya J: Activation
of Src, Fyn and Yes non-receptor tyrosine kinases in keratinocytes
expressing human papillomavirus (HPV) type 16 E7 oncoprotein. Virol
J. 10:792013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lu X, Hu X, Song L, An L, Duan M, Chen S
and Zhao S: SH2 domain is crucial for function of Fyn in neuronal
migration and cortical lamination. BMB Rep. 48:97–102. 2015.
View Article : Google Scholar :
|
|
22
|
Posadas EM, Al-Ahmadie H, Robinson VL,
Jagadeeswaran R, Otto K, Kasza KE, Tretiakov M, Siddiqui J, Pienta
KJ, Stadler WM, et al: FYN is overexpressed in human prostate
cancer. BJU Int. 103:171–177. 2009. View Article : Google Scholar :
|
|
23
|
Yadav V and Denning MF: Fyn is induced by
Ras/PI3K/Akt signaling and is required for enhanced
invasion/migration. Mol Carcinog. 50:346–352. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gujral TS, Chan M, Peshkin L, Sorger PK,
Kirschner MW and MacBeath G: A noncanonical Frizzled2 pathway
regulates epithelial-mesenchymal transition and metastasis. Cell.
159:844–856. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Elias D, Vever H, Laenkholm AV, Gjerstorff
MF, Yde CW, Lykkesfeldt AE3 and Ditzel HJ: Gene expression
profiling identifies FYN as an important molecule in tamoxifen
resistance and a predictor of early recurrence in patients treated
with endocrine therapy. Oncogene. 2014.PubMed/NCBI
|
|
26
|
Ninio-Many L, Grossman H, Shomron N,
Chuderland D and Shalgi R: microRNA-125a-3p reduces cell
proliferation and migration by targeting Fyn. J Cell Sci.
126:2867–2876. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu L, Lin Q, Liao H, Feng J, Dong X and Ye
J: TGF-β1 induces podocyte injury through Smad3-ERK-NF-κB pathway
and Fyn-dependent TRPC6 phosphorylation. Cell Physiol Biochem.
26:869–878. 2010. View Article : Google Scholar
|
|
28
|
Hardy KM, Yatskievych TA, Konieczka J,
Bobbs AS and Antin PB: FGF signalling through RAS/MAPK and PI3K
pathways regulates cell movement and gene expression in the chicken
primitive streak without affecting E-cadherin expression. BMC Dev
Biol. 11:202011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Roy SK, Srivastava RK and Shankar S:
Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of
FOXO transcription factor, leading to cell cycle arrest and
apoptosis in pancreatic cancer. J Mol Signal. 5:102010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Saito YD, Jensen AR, Salgia R and Posadas
EM: Fyn: A novel molecular target in cancer. Cancer. 116:1629–1637.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Singh MM, Howard A, Irwin ME, Gao Y, Lu X,
Multani A and Chandra J: Expression and activity of Fyn mediate
proliferation and blastic features of chronic myelogenous leukemia.
PLoS One. 7:e516112012. View Article : Google Scholar
|
|
32
|
Kawakami T, Kawakami Y, Aaronson SA and
Robbins KC: Acquisition of transforming properties by FYN, a normal
SRC-related human gene. Proc Natl Acad Sci USA. 85:3870–3874. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yeo MG, Oh HJ, Cho HS, Chun JS,
Marcantonio EE and Song WK: Phosphorylation of Ser 21 in Fyn
regulates its kinase activity, focal adhesion targeting, and is
required for cell migration. J Cell Physiol. 226:236–247. 2011.
View Article : Google Scholar
|
|
34
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: Acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Smyth D, Leung G, Fernando M and McKay DM:
Reduced surface expression of epithelial E-cadherin evoked by
interferon-gamma is Fyn kinase-dependent. PLoS One. 7:e384412012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kim AN, Jeon WK, Lim KH, Lee HY, Kim WJ
and Kim BC: Fyn mediates transforming growth factor-beta1-induced
down-regulation of E-cadherin in human A549 lung cancer cells.
Biochem Biophys Res Commun. 407:181–184. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wakahashi S, Sudo T, Oka N, Ueno S,
Yamaguchi S, Fujiwara K, Ohbayashi C and Nishimura R: VAV1
represses E-cadherin expression through the transactivation of
Snail and Slug: A potential mechanism for aberrant epithelial to
mesenchymal transition in human epithelial ovarian cancer. Transl
Res. 162:181–190. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vuoriluoto K, Haugen H, Kiviluoto S,
Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB and Ivaska J:
Vimentin regulates EMT induction by Slug and oncogenic H-Ras and
migration by governing Axl expression in breast cancer. Oncogene.
30:1436–1448. 2011. View Article : Google Scholar
|
|
39
|
Lee SJ, Jung YH, Oh SY, Yong MS, Ryu JM
and Han HJ: Netrin-1 induces MMP-12-dependent E-cadherin
degradation via the distinct activation of PKCalpha and FAK/Fyn in
promoting mesenchymal stem cells motility. Stem Cells Dev.
23:1870–1882. 2014. View Article : Google Scholar : PubMed/NCBI
|
